ECM
NBIX icon

ExodusPoint Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

ExodusPoint Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,830
Closed -$4.51M – 1904
2025
Q4 		$4.51M Sell
31,830
-602
-2% -$87.2K 0.04% 505
2025
Q3 		$4.55M Sell
32,432
-40,167
-55% -$5.44M 0.05% 446
2025
Q2 		$9.13M Buy
72,599
+70,185
+2,907% +$8.05M 0.08% 253
2025
Q1 		$267K Sell
2,414
-13,430
-85% -$1.7M ﹤0.01% 1250
2024
Q4 		$2.16M Buy
+15,844
New +$1.96M 0.01% 687
2024
Q3 		– Sell
-13,304
Closed -$1.83M – 1932
2024
Q2 		$1.83M Sell
13,304
-24,050
-64% -$3.3M 0.01% 814
2024
Q1 		$5.15M Sell
37,354
-8,710
-19% -$1.19M 0.04% 376
2023
Q4 		$6.07M Buy
46,064
+14,276
+45% +$1.64M 0.04% 304
2023
Q3 		$3.58M Sell
31,788
-84,917
-73% -$8.94M 0.03% 463
2023
Q2 		$11M Sell
116,705
-57,295
-33% -$5.6M 0.09% 231
2023
Q1 		$17.6M Buy
174,000
+100,994
+138% +$10.5M 0.15% 141
2022
Q4 		$8.72M Buy
73,006
+22,025
+43% +$2.58M 0.13% 203
2022
Q3 		$5.42M Sell
50,981
-12,207
-19% -$1.24M 0.07% 374
2022
Q2 		$6.16M Buy
63,188
+16,066
+34% +$1.48M 0.08% 337
2022
Q1 		$4.42M Sell
47,122
-19,618
-29% -$1.66M 0.06% 434
2021
Q4 		$5.68M Buy
66,740
+40,867
+158% +$3.76M 0.06% 389
2021
Q3 		$2.48M Sell
25,873
-29,521
-53% -$2.79M 0.03% 642
2021
Q2 		$5.39M Buy
+55,394
New +$5.31M 0.06% 327
2021
Q1 		– Sell
-6,983
Closed -$669K – 2432
2020
Q4 		$669K Sell
6,983
-11,840
-63% -$1.14M 0.01% 1073
2020
Q3 		$1.81M Sell
18,823
-7,353
-28% -$851K 0.04% 442
2020
Q2 		$3.19M Sell
26,176
-2,913
-10% -$322K 0.08% 275
2020
Q1 		$2.52M Buy
+29,089
New +$2.85M 0.14% 148
2019
Q4 		– Sell
-44,746
Closed -$4.03M – 1755
2019
Q3 		$4.03M Buy
44,746
+6,907
+18% +$645K 0.14% 135
2019
Q2 		$3.19M Sell
37,839
-14,219
-27% -$1.17M 0.13% 108
2019
Q1 		$4.59M Buy
52,058
+37,225
+251% +$3.11M 0.34% 53
2018
Q4 		$1.06M Buy
+14,833
New +$1.42M 0.07% 86

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's NBIX Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 31,830 shares — an estimated $4.51M sold.

ExodusPoint Capital Management first reported a position in NBIX in Q4 2018 and held it in 26 quarters. The position peaked at $17.6M in Q1 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 31,830 Neurocrine Biosciences shares in Q1 2026, an estimated $4.51M.
  • ExodusPoint Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 26 quarters.
  • ExodusPoint Capital Management's Neurocrine Biosciences position peaked at $17.6M in Q1 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.